Expert NetworkExpert InterviewMRK

Slingshot members are talking to an expert! The topic is:

Evaluating Merck's data for enlicitide decanoate (Oral PCSK9 Inhibitor) in lowering LDL-C versus existing non-statin therapies

Executed on:Apr 17, 2026 2:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Utah Lipid Center
  • President and Director of the Utah Lipid Center and past president of the American Board of Clinical Lipidology.
  • Treats 50 patients with hypertriglyceridemia (SHTG)
  • Responsible for writing guidelines for the American Heart Association and the American Association of Clinical Endocrinology; has co-authored over 160 scientific articles, reviews, book chapters.

Interview Goal

We aim to discuss the clinical and commercial potential of Merck & Co.’s enlicitide decanoate by understanding physician perspectives on efficacy, differentiation vs. existing non-statin therapies, patient adoption, and its potential role in the evolving LDL-C treatment landscape.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.